Download PDF
Open Access
CC BY 4.0 · Glob Med Genet 2024; 11(02): 150-158
DOI: 10.1055/s-0044-1786004
Original Article

Prevalence and Associations of Co-occurrence of NFE2L2 Mutations and Chromosome 3q26 Amplification in Lung Cancer

Authors

  • Jinfeng Liu

    1   Department of Thoracic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China

  • Sijie Liu

    2   Department of Thoracic Surgery, Beijing Aerospace General Hospital, Beijing, China

  • Dan Li

    3   Department of General Surgery, Jingxing County Hospital of Hebei Province, Shijiazhuang, China

  • Hongbin Li

    4   Department of Oncology, Rongcheng County People's Hospital, Baoding, China

  • Fan Zhang

    5   Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

Funding This study was funded by the National Key R&D Program of China (grant number: 2021YFC2500900).
Further Information
Also available at
  Permissions and Reprints

Abstract

Background NFE2L2 (nuclear factor erythroid-2-related factor-2) encodes a basic leucine zipper (bZIP) transcription factor and exhibits variations in various tumor types, including lung cancer. In this study, we comprehensively investigated the impact of simultaneous mutations on the survival of NFE2L2-mutant lung cancer patients within specific subgroups.

Methods A cohort of 1,103 lung cancer patients was analyzed using hybridization capture-based next-generation sequencing.

Results The NFE2L2 gene had alterations in 3.0% (33/1,103) of lung cancer samples, including 1.5% (15/992) in adenocarcinoma and 16.2% (18/111) in squamous cell carcinoma. Thirty-four variations were found, mainly in exons 2 (27/34). New variations in exon 2 (p.D21H, p.V36_E45del, p.F37_E45del, p.R42P, p.E67Q, and p.L76_E78delinsQ) were identified. Some patients had copy number amplifications. Co-occurrence with TP53 (84.8%), CDKN2A (33.3%), KMT2B (33.3%), LRP1B (33.3%), and PIK3CA (27.3%) mutations was common. Variations of NFE2L2 displayed the tightest co-occurrence with IRF2, TERC, ATR, ZMAT3, and SOX2 (p < 0.001). In The Cancer Genome Atlas Pulmonary Squamous Carcinoma project, patients with NFE2L2 variations and 3q26 amplification had longer median survival (63.59 vs. 32.04 months, p = 0.0459) and better overall survival.

Conclusions NFE2L2 mutations display notable heterogeneity in lung cancer. The coexistence of NFE2L2 mutations and 3q26 amplification warrants in-depth exploration of their potential clinical implications and treatment approaches for affected patients.

Keywords

NFE2L2 - lung cancer - 3q36 amplification - co-occurrence mutations - next-generation sequencing

Availability of Data and Materials

The majority of data presented in the study are included in the article; further inquiries can be directed to the corresponding author.


Authors' Contributions

J.L. contributed to data curation. S.L., D.L., and F.Z. helped in investigation. H.L. and F.Z. helped in writing—review, editing, and resources. S.L., H.L., and F.Z. helped in supervision. J.L. contributed to visualization and writing—original draft. All authors have read and agreed to the published version of the manuscript.


Supplementary Material



Publication History

Article published online:
15 April 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany